IL1B and deep vein thrombosis: Conversely, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study demonstrated that interleukin-1β (IL-1β) antagonist canakinumab reduced the rate of recurrent CV events in patients with a prior MI and elevated hs-CRP levels.91